HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Arjan A van de Loosdrecht Selected Research

invariant chain (Ii-Key)

12/2014Class II-associated invariant chain peptide as predictive immune marker in minimal residual disease in acute myeloid leukemia.
6/2014High class II-associated invariant chain peptide expression on residual leukemic cells is associated with increased relapse risk in acute myeloid leukemia.
3/2012Tumor immune escape in acute myeloid leukemia: Class II-associated invariant chain peptide expression as result of deficient antigen presentation.
11/2011Class II-associated invariant chain peptide expression represents a novel parameter for flow cytometric detection of acute promyelocytic leukemia.
4/2011Absence of class II-associated invariant chain peptide on leukemic blasts of patients promotes activation of autologous leukemia-reactive CD4+ T cells.
3/2010Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Arjan A van de Loosdrecht Research Topics

Disease

29Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
12/2021 - 08/2004
22Neoplasms (Cancer)
10/2020 - 11/2004
20Leukemia
01/2020 - 03/2004
18Myelodysplastic Syndromes (Myelodysplastic Syndrome)
07/2021 - 04/2009
7Residual Neoplasm
12/2014 - 03/2006
3Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic)
01/2017 - 01/2014
3Blister (Bulla)
11/2015 - 01/2014
3Lymphoma (Lymphomas)
08/2010 - 03/2004
3Non-Hodgkin Lymphoma (Lymphosarcoma)
01/2008 - 11/2004
2Hematologic Neoplasms (Hematological Malignancy)
10/2021 - 08/2020
2Diffuse Scleroderma (Progressive Systemic Sclerosis)
01/2021 - 06/2014
1Paroxysmal Hemoglobinuria (Paroxysmal Nocturnal Hemoglobinuria)
11/2021
1Hemostatic Disorders
10/2021
1Anemia
10/2021
1Blood Platelet Disorders (Thrombocytopathy)
10/2021
1Infections
10/2021
1Refractory Anemia with Excess of Blasts (RAEM)
01/2019
1Melanoma (Melanoma, Malignant)
01/2019
1Chromosome Aberrations (Chromosome Abnormalities)
01/2019
1Mitochondrial Diseases (Mitochondrial Disease)
11/2016
1Cytopenia
02/2016
1B-Cell Leukemia (Leukemia, B Cell)
07/2014
1Systemic Scleroderma (Systemic Sclerosis)
06/2014
1Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
04/2013
1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL)
04/2013
1Acute Promyelocytic Leukemia
11/2011
1Hemorrhage
11/2011
1BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
04/2011
1Refractory Anemia
07/2010
1Thrombocytosis (Thrombocythemia)
07/2010
1Virus Diseases (Viral Diseases)
12/2009

Drug/Important Bio-Agent (IBA)

17AntigensIBA
11/2021 - 08/2004
8VaccinesIBA
10/2018 - 01/2006
8Peptides (Polypeptides)IBA
11/2015 - 01/2010
6invariant chain (Ii-Key)IBA
12/2014 - 03/2010
5Azacitidine (5 Azacytidine)FDA Link
01/2019 - 12/2011
4Proteins (Proteins, Gene)FDA Link
10/2020 - 01/2008
3Biomarkers (Surrogate Marker)IBA
12/2021 - 03/2010
3Interleukin-4 (Interleukin 4)IBA
11/2015 - 01/2003
3Histocompatibility Antigens Class IIIBA
04/2011 - 03/2010
2RNA Splicing FactorsIBA
01/2021 - 01/2020
2CytokinesIBA
04/2014 - 01/2003
2Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA
01/2014 - 01/2003
2Lenalidomide (CC 5013)FDA Link
04/2013 - 07/2010
2HLA-DR Antigens (HLA-DR)IBA
04/2011 - 03/2010
2Imatinib Mesylate (Gleevec)FDA Link
04/2011 - 07/2006
2T-Cell Antigen Receptors (T-Cell Receptor)IBA
04/2011 - 04/2009
2Monoclonal AntibodiesIBA
08/2010 - 01/2006
1luspaterceptIBA
01/2021
1Biological ProductsIBA
10/2020
1ThrombomodulinIBA
01/2020
1LigandsIBA
01/2019
1Mannose (D-Mannose)IBA
01/2019
1Immune Checkpoint InhibitorsIBA
01/2019
1DC-specific ICAM-3 grabbing nonintegrin (DC-SIGN)IBA
01/2019
1Polysaccharides (Glycans)IBA
01/2019
1Transcription Factor 4IBA
01/2019
1IronIBA
01/2018
1Transferrin (beta 2 Transferrin)IBA
01/2018
1Transferrin Receptors (Transferrin Receptor)IBA
01/2018
1Growth Differentiation Factor 15IBA
01/2018
1Cytarabine (Cytosar-U)FDA LinkGeneric
03/2017
1Clofarabine (Clolar)FDA Link
03/2017
1Amsacrine (AMSA)IBA
03/2017
1DiamondIBA
11/2016
1PlasticsIBA
02/2016
1Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA
07/2014
1Cyclophosphamide (Cytoxan)FDA LinkGeneric
06/2014
1EpitopesIBA
04/2014
1MicroRNAs (MicroRNA)IBA
04/2013
1Peroxidase (Myeloperoxidase)IBA
03/2013
1Sudan Black BIBA
03/2013
1Bevacizumab (Avastin)FDA Link
12/2012
1Ferritins (Ferritin)IBA
09/2012
1L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA
09/2012
1Tretinoin (Retinoic Acid)FDA LinkGeneric
11/2011
1Tyrosine Kinase InhibitorsIBA
04/2011
1Histocompatibility Antigens Class IIBA
04/2011
1Dasatinib (BMS 354825)FDA Link
04/2011
1nilotinibFDA Link
04/2011
1Proteasome Endopeptidase Complex (Proteasome)IBA
12/2010
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
03/2010
1Cancer VaccinesIBA
01/2010
1SuspensionsIBA
01/2010
1RNA (Ribonucleic Acid)IBA
01/2010
1DNA (Deoxyribonucleic Acid)IBA
01/2010
1Granzymes (Granzyme)IBA
04/2009
1Tryptophan (L-Tryptophan)FDA Link
12/2008
1Messenger RNA (mRNA)IBA
12/2008

Therapy/Procedure

14Immunotherapy
08/2020 - 03/2004
12Therapeutics
10/2021 - 03/2004
7Surgical Instruments (Clip)
06/2014 - 08/2004
6Drug Therapy (Chemotherapy)
01/2019 - 11/2004
4Hematopoietic Stem Cell Transplantation
10/2021 - 06/2014
2Stem Cell Transplantation
01/2016 - 12/2009
2Investigational Therapies (Experimental Therapy)
01/2011 - 01/2010
1Erythrocyte Transfusion
01/2018
1Transplantation
01/2017
1Homologous Transplantation
01/2016
1Aftercare (After-Treatment)
06/2014